ABN 16 165 160 841

ASX RELEASE **20 December 2022**

LETTER TO SHAREHOLDERS: END OF YEAR SUMMARY AND PLANS FOR 2023

Dear Shareholder,

As 2022 draws to a close, I would like to take a moment to extend my most sincere gratitude to each and every one of Amplia Therapeutics' (ASX:ATX) supporters. We are backed by an enviable network of investors, corporate leaders, clinical and scientific experts, and other stakeholders who are truly invested in our journey.

Over the last 12 months, the Amplia team has executed our clinical and business development program with purpose and enthusiasm, bringing us closer to changing the treatment landscape for people diagnosed with cancer and fibrotic diseases.

As a long-standing member of the Board, and recently appointed CEO and MD, it has been extremely encouraging to witness this energy in action, and I am confident that we are on track for a successful and transformative year ahead.

Investor presentation

We have prepared an Investor Presentation showcasing some of the highlights of the last 12 months, and outlining our plans for 2023, appended here and available on our website (https://www.ampliatx.com/site/investor-information/current-presentations)

Key achievements in 2022 include:

- Following ethics clearance, the Company commenced recruitment into the ACCENT trial [1] of our lead drug candidate, AMP945 in first-line pancreatic cancer patients. The response to the trial has been extremely positive, and recruitment for the first cohort is now complete[2].
- Presented the design and rationale for the ACCENT trial to a global audience at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer[3]
- Released new preclinical data showing comparable efficacy of AMP945 to current standard of care in an animal model of lung fibrosis[4], providing compelling encouragement for potential clinical trials of AMP945 in idiopathic pulmonary fibrosis.
- Progressed the clinical development of our second FAK inhibitor, AMP886, including the report of preclinical data demonstrating its potential as a treatment for acute myeloid leukemia[5].
- Received a $1.8m R&D tax refund[6] as part of the Australian Government's Research and Development Tax Incentive Refund scheme.

[1] ASX Announcement – First Patient Recruited to ACCENT Trial in Pancreatic Cancer, 2 August 2022
[2] ASX Announcement – ACCENT Trial Recruitment Progress, 29 November 2022
[3] ASX Announcement – Presentation at Major Pancreatic Cancer Conference, 25 July 2022
[4] ASX Announcement – AMP945 Shows Efficacy in Model of Lung Fibrosis, 2 June 2022
[5] ASX Announcement – AMP886 Activity in Acute Myeloid Leukemia (AML), 3 October 2022
[6] ASX Announcement – Amplia Receives $1.8m R&D Tax Incentive

Amplia in the News

The progress of our ACCENT Clinical Trial has consistently captured the attention of top tier and industry press this year. A definite highlight was a story filmed with Channel 9 News and the Garvan Institute, showcasing the scientific potential of AMP945.

Click here to watch the Channel 9 News story (https://www.youtube.com/watch?v=sZnOG7KgLLM)

I anticipate plenty of positive news to share with our shareholders as we continue to progress the ACCENT trial, and move through our planned clinical and corporate milestones. I thank you for your support as we continue this journey.

I wish you and your loved ones a safe and restful break over the festive season.

With thanks,

Dr Chris Burns
Amplia CEO and MD

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics

- End -

For Further Information
info@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in cancer and Amplia has a particular development focus in fibrotic tumours such as pancreatic and ovarian cancers. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF) and the Company is also developing its FAK inhibitors in these indications.

Amplia

ampliatx.com

2022 Year in Review and Growth Plans for 2023

December 2022

Important Notice and Disclaimer

This presentation (**Presentation**) contains summary information about Amplia Therapeutics Limited ACN 165 160 841 and its subsidiaries (the **Company** or **Amplia**) which is current as at 16 December 2022. By attending an investor presentation or briefing, or accepting, accessing or reviewing this Presentation, you acknowledge and agree to the terms set out below.

Summary Information: This Presentation has been prepared for information purposes only and is a summary only. It should be read in conjunction with Amplia's most recent financial report and other periodic and continuous disclosure information lodged with the Australian Securities Exchange (ASX), which is available at www.asx.com.au. Subject only to any legal obligation to do so, the Company does not have any obligation to correct or update the content of this Presentation.

Not financial product advice: This Presentation does not, and does not purport to, contain all information necessary to make an investment decision, is not intended as investment or financial advice (nor tax, accounting or legal advice) and must not be relied upon as such. This Presentation does not take into account the investment objectives, financial situation or needs of any particular investor. Investors are encouraged to seek independent professional advice when deciding if an investment in the Company is appropriate. The Company is not licensed to provide financial product advice in respect of its own securities. This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (or any other law). It is not, and does not constitute, an invitation or offer of securities for subscription, purchase or sale in any jurisdiction.

Investment risk and past performance: An investment in Amplia shares is subject to known and unknown risks, some of which are beyond the control of the Company and its directors. The Company does not guarantee any particular rate of return or the performance of Amplia. Past performance is not, and should not be relied on as being, indicative of future performance.

Future performance and forward-looking statements: This Presentation includes forward looking statements, which can generally be identified by the use of words such as "may", "will", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. They may include, without limitation, statements regarding plans, strategies and objectives and anticipated business developments. Forward-looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause Amplia's actual results, performance and achievements to differ materially from statements in this Presentation. Forward-looking statements are based on the Company's good faith assumptions as to the financial, market, regulatory and other relevant environments that will exist and affect Amplia's business and operations in the future. The Company does not give any assurance that the assumptions will prove to be correct.There may be other factors that could cause actual results or events not to be as anticipated, and many events are beyond the reasonable control of the Company. Readers are cautioned not to place undue reliance on forward-looking statements, **particularly in the current economic climate and given the significant volatility, uncertainty and disruption caused by the COVID-19 pandemic**. Forward-looking statements in this Presentation are only made as at the date of this Presentation and the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

Industry data and third party information: Industry data and third party information used in this Presentation may have been obtained from research, surveys, reports or studies conducted by third parties, including industry or general publications. Neither Amplia not its representatives have independently verified any such market or industry data.

Financial Information: This Presentation contains historical financial information based on the Company's results for the 12 month period ending 31 December 2022. All financial information disclosed in this Presentation is presented in Australian dollars unless otherwise noted. Any discrepancies between totals and sums of components in tables and figures contained in this Presentation are due to rounding.

Disclaimer: To the maximum extent permitted by law, Amplia and its officers, directors, employees, agents and advisers: (1) disclaim all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation; (2) disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions; and (3) do not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the information in this Presentation or that this Presentation contains all material information about Amplia or that a prospective investor or purchaser may require in evaluating a possible investment in Amplia or acquisition of shares, or the likelihood of fulfilment of any forward-looking statement.

Milestones acomplished in 2022

- Commenced recruitment of patients for ACCENT trial in Pancreatic Cancer
- Recruitment for first cohort of patients completed
- Demonstrated increased survival in pre-clinical Pancreatic Cancer model
- Completed 90 day toxicology study to support 3 month clinical dosing
- Positive results in comparison with market leader in pre-clinical pulmonary fibrosis model
- Positive results of second FAK inhibitor, AMP886, in preclinical model of acute myeloid leukemia

Pancreatic Cancer



ACCENT Clinical Trial

- **Apr:** Received HREC approval
- **May:** Pre-IND meeting completed
- **Aug:** First patient recruited
- **Sep:** ACCENT trial presented at AACR
- **Nov:** First dosing cohort recruitment complete

Pre-clinical Studies

- **Feb:** Increased survival demonstrated in human pancreatic cancer model

Chemistry, Manufacturing, Controls

- **Jul:** Completed manufacture of 5kg batch of AMP945 demonstrating that scale up could be achieved
- **Feb:** Completed manufacture of first batch of capsules
- **May:** Completed manufacture of remaining capsules required for trial

IPF

Idiopathic Pulmonary Fibrosis



Toxicology Studies

- **Aug:** Completed 90 day toxicology studies that support chronic dosing studies for up to 3 months

Pre-clinical Studies

- **Jul:** AMP945 shown to be as effective as current market leader Ofev® (nintedanib) in industry-standard model of IPF

Chemistry, Manufacturing, Controls

- **Aug:** Manufactured sufficient capsules for a 3 month clinical trial

AML

Acute Myeloid Leukaemia



Pre-clinical Studies

- **Oct:** AMP886, a second FAK inhibitor, was shown to inhibit acute myeloid leukemia (AML) in an industry-standard model of disease

Chemistry, Manufacturing, Controls

- **Aug:** Sufficient AMP886 has been manufactured for pre-clinical studies

New Team Members

We have continued to grow the Amplia Team to increase our expertise across the breadth of pre-clinical and clinical studies, and manufacturing

Chris Burns
CEO and Managing Director

November 2022

Anthony Bishop
Principal Development Manager

February 2022

Terrie-Anne Cock
Head of Translational Biology

July 2022

Adrian Sulistio
CMC Project Manager

May 2022

Growth Plans for 2023

- Complete dose selection for ACCENT Trial
- Commence Part B of ACCENT Trial
- Commence process improvement for manufacturing
- Submit IND to US FDA
- Progress towards a second clinical trial with AMP945
- Continue to progress the development of AMP886

Thank You.

Amplia Therapeutics Limited
ABN 16 165 160 841
ASX: ATX
info@ampliatx.com
ampliatx.com

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com